Pharma Deals Review, Vol 2010, No 7 (2010)

Font Size:  Small  Medium  Large

Sanofi-aventis Acquires TargeGen to Strengthen its Oncology Pipeline

Staff Editor

Abstract


Sanofi-aventis is acquiring TargeGen, a developer of small molecule kinase inhibitors for the treatment of various types of cancers, in a deal potentially valued at US$560 M.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.